Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhelion Life SciencesTRUFF -14.58% 3-Year EBITDA Growth Rate is -4.60% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 811 Drug Manufacturers companies, Rhelion Life Sciences ranks worse than 73.74% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -4.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rhelion Life Sciences was 42.00% per year. The lowest was -244.80% per year. And the median was -28.60% per year.
Rhelion Life Sciences (OTCPK:TRUFF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rhelion Life Sciences 3-Year EBITDA Growth Rate Related Terms
TRUFF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhelion Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhelion Life Sciences 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhelion Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rhelion Life Sciences's 3-Year EBITDA Growth Rate falls into.
Rhelion Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -4.60% mean?
Rhelion Life Sciences (TRUFF) has a 3-Year EBITDA Growth Rate of -4.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rhelion Life Sciences and its competitors. According to the industry distribution chart, Rhelion Life Sciences ranks #598 out of 811 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is Rhelion Life Sciences' 3-Year EBITDA Growth Rate too high?
Rhelion Life Sciences' current 3-Year EBITDA Growth Rate is -4.60%. Based on the distribution chart, Rhelion Life Sciences ranks #598 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Rhelion Life Sciences' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Rhelion Life Sciences ranks #598 out of 811 companies for 3-Year EBITDA Growth Rate. This places Rhelion Life Sciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rhelion Life Sciences and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhelion Life Sciences's current 3-Year EBITDA Growth Rate is -4.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhelion Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Rhelion Life Sciences (TRUFF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.02 — trading 48.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -4.60%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rhelion Life Sciences (TRUFF), the current 3-Year EBITDA Growth Rate is -4.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red Light Holland Corp is engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands. Its products include Microdosing Kit and Merch. Its revenue is comprised of sales of wholesale truffles, cannabis seeds, and other cannabis products and sales of microdose packs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRUFF has been successfully added to your 
